Glaukos Corp Files 8-K on Equity Sales
Ticker: GKOS · Form: 8-K · Filed: Jun 28, 2024 · CIK: 1192448
Sentiment: neutral
Topics: equity-sale, filing, sec
Related Tickers: GLKS
TL;DR
GLKS filed an 8-K for unregistered equity sales - watch for dilution.
AI Summary
Glaukos Corporation filed an 8-K on June 28, 2024, reporting unregistered sales of equity securities and other events. The filing details the company's principal executive offices located at One Glaukos Way, Aliso Viejo, California, 92656, and its telephone number is (949) 367-9600. The report is filed under the 1934 Securities Exchange Act.
Why It Matters
This filing indicates potential dilution or changes in share structure due to unregistered equity sales, which could impact existing shareholders.
Risk Assessment
Risk Level: medium — Unregistered sales of equity securities can sometimes signal financial distress or lead to dilution, requiring careful monitoring.
Key Players & Entities
- Glaukos Corporation (company) — Registrant
- June 28, 2024 (date) — Date of earliest event reported
- One Glaukos Way, Aliso Viejo, California, 92656 (location) — Principal executive offices
- 949-367-9600 (phone_number) — Registrant's telephone number
FAQ
What type of equity securities were sold unregistered?
The filing does not specify the type of equity securities sold unregistered, only that such sales occurred.
Were these sales part of a private placement or other exemption from registration?
The filing indicates 'Unregistered Sales of Equity Securities' but does not detail the specific exemption or nature of the offering.
What is the significance of 'Other Events' being reported?
The filing lists 'Other Events' as a category, but the specific details of these events are not elaborated upon in the provided text.
When was Glaukos Corporation incorporated?
Glaukos Corporation was incorporated in Delaware, as indicated by the filing.
What is Glaukos Corporation's SIC code?
Glaukos Corporation's Standard Industrial Classification (SIC) code is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 566 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-06-28 16:47:30
Key Financial Figures
- $230,000,000 — nge Transactions, the holders exchanged $230,000,000 in aggregate principal amount of the Ex
Filing Documents
- tm2418355d1_8k.htm (8-K) — 26KB
- 0001104659-24-076328.txt ( ) — 193KB
- gkos-20240628.xsd (EX-101.SCH) — 3KB
- gkos-20240628_lab.xml (EX-101.LAB) — 33KB
- gkos-20240628_pre.xml (EX-101.PRE) — 22KB
- tm2418355d1_8k_htm.xml (XML) — 3KB
02 Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities. The disclosure under Item 8.01 below is incorporated by reference herein. Glaukos Corporation (the " Company ") issued the Shares (as defined below) pursuant to separate, privately negotiated exchange agreements (the " Exchange Agreements "), and in reliance on the exemption from the registration requirements of the Securities Act of 1933, as amended (the " Securities Act "), provided by Section 4(a)(2) of the Securities Act. The Shares were issued only to investors that qualified as "qualified institutional buyers" (as such term is defined in Rule 144A of the Securities Act) and institutional "accredited investors" (as such term is defined in Rule 501 of the Securities Act).
01 Other Events
Item 8.01 Other Events. On June 28, 2024, the Company closed the transactions contemplated by the Exchange Agreements that it had previously announced on June 14, 2024 (the " Exchange Transactions ") with certain holders of the Company's 2.75% Convertible Senior Notes due 2027 (the " Existing Convertible Notes "). In the Exchange Transactions, the holders exchanged $230,000,000 in aggregate principal amount of the Existing Convertible Notes for consideration consisting of an aggregate of 4,253,423 shares of the Company's common stock (the " Shares "), and cash in lieu of fractional shares and in respect of accrued interest on the Existing Convertible Notes. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GLAUKOS CORPORATION Date: June 28, 2024 By: /s/ Alex R. Thurman Name: Alex R. Thurman Title: Senior Vice President & Chief Financial Officer